Acousia Therapeutics GmbH, a Tübingen, Germany-based leader in the discovery and development of novel therapies in inner ear-related diseases and pathologies, raised close to €10m in Series B funding.
Backers included LBBW Ventures, Bregua Corporation, Boehringer Ingelheim Venture Fund (BIVF), Kreditanstalt für Wiederaufbau (KfW), and Creathor Ventures.
The investment will enable the company to advance the development of small molecules-based drug candidates.
Founded in 2012 by the three partners Prof. Hubert Löwenheim, EMC Microcollections GmbH and BIVF and led by Dr. Christoph Antz, CEO, Acousia has developed drug candidates that will protect, repair and restore sensory hair cell function in patients suffering from hearing loss, caused by ototoxic drugs, normal aging process, noise and other conditions like sudden deafness.
The company’s most advanced drug candidate ACOU085 is being developed for clinical application in otoprotection (cisplatin-related) and will be profiled in
functional improvement of hair cells.